Enavate Sciences Gp, LLC

In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Enavate Sciences Gp, LLC reported 5 stock positions worth $139.2 million. Its top holding was Upstream Bio (UPB) at 29.0% of the portfolio, followed by Immunome (IMNM, 26.5%) and Zenas Biopharma (ZBIO, 22.1%).

Most Recent 13F
Q2 2026
Location
New York, NY
CIK
0001953107
Portfolio Value
$139.2M (Q4 2024)
SEC Filing
0001104659-25-014094 ↗ filed Feb 14, 2025

Holdings Value

0$200.0M$400.0M$600.0M Q4 2024: $139.2M $139.2M Q4 2024 Q1 2025: $132.7M Q1 2025 Q2 2025: $176.5M Q2 2025 Q3 2025: $327.5M Q3 2025 Q4 2025: $506.8M Q4 2025 Q1 2026: $351.5M Q1 2026 Q2 2026: $345.4M Q2 2026

Holdings 5 stocks · $139.2M
UPB Upstream Bio Inc. 29.04% 2,459,703 $40.4M —
IMNM Immunome Inc. 26.53% 3,478,261 $36.9M —
ZBIO Zenas Biopharma Inc. 22.12% 3,761,359 $30.8M —
CAMP CAMP4 Therapeutics Corp. 14.19% 3,785,802 $19.8M —
CMPX Compass Therapeutics Inc. 8.11% 7,788,150 $11.3M —

Portfolio Sells Q4 2024

No earlier filing to compare with.

Portfolio Buys Q4 2024

No earlier filing to compare with.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 7$345.4MSION, ZBIO, IMNM, BBOT, CMPX
Q1 2026 7$351.5MSION, IMNM, ZBIO, CMPX, BBOT
Q4 2025 7$506.8MZBIO, IMNM, SION, UPB, CMPX
Q3 2025 7$327.5MZBIO, SION, IMNM, UPB, BBOT
Q2 2025 6$176.5MIMNM, SION, ZBIO, UPB, CMPX
Q1 2025 6$132.7MIMNM, ZBIO, SION, CAMP, UPB
Q4 2024 5$139.2MUPB, IMNM, ZBIO, CAMP, CMPX